Regorafenib is an oral kinase inhibitor with a broad spectrum of activity. It is used to treat metastatic colorectal cancer, advanced gastrointestinal stromal tumors, and hepatocellular carcinoma. Initially approved by the FDA on September 27, 2012, it was later expanded in April 2017 to include the treatment of hepatocellular carcinoma. Regorafenib is indicated for patients with metastatic colorectal cancer who have previously undergone various chemotherapy regimens, anti-VEGF therapy, and, if they have wild-type KRAS, anti-EGFR therapy. It is also used for patients with locally advanced, unresectable, or metastatic gastrointestinal stromal tumors who have been previously treated with imatinib mesylate and sunitinib malate. Additionally, it's prescribed for patients with hepatocellular carcinoma who have received prior treatment with sorafenib. Regorafenib functions as an inhibitor of multiple kinases, playing a role in normal cellular processes and pathological conditions like oncogenesis, tumor angiogenesis, and the maintenance of the tumor microenvironment.

Regorafenib Pathway References